ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,066.00
-0.07%
S&P 500
5,303.27
0.12%
US Dollar vs CAD
1.36175
0.00%
Bitcoin
66,937.33
-0.21%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ocular Therapeutix Inc (OCUL)

  7. Ocular Therapeutix Inc (OCUL) News

OCUL

Ocular Therapeutix (OCUL)

Ocular Therapeutix Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OCUL
DateTimeSourceHeadlineSymbolCompany
05/07/20243:22PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
05/07/20243:20PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCULOcular Therapeutix Inc
05/07/20243:05PMGlobeNewswire Inc.Ocular Therapeutix™ Reports First Quarter 2024 ResultsNASDAQ:OCULOcular Therapeutix Inc
05/07/20243:01PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:OCULOcular Therapeutix Inc
05/06/20247:16PMGlobeNewswire Inc.Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OCULOcular Therapeutix Inc
05/06/20246:30AMGlobeNewswire Inc.Ocular Therapeutix™ to Present at Two Upcoming Investor ConferencesNASDAQ:OCULOcular Therapeutix Inc
05/03/20246:30AMGlobeNewswire Inc.Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024NASDAQ:OCULOcular Therapeutix Inc
05/01/20246:30AMGlobeNewswire Inc.Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024NASDAQ:OCULOcular Therapeutix Inc
03/11/20243:23PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
03/11/20243:12PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OCULOcular Therapeutix Inc
03/11/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCULOcular Therapeutix Inc
03/11/20245:39AMIH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:OCULOcular Therapeutix Inc
02/27/20243:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/26/20247:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/26/20247:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/26/20247:04PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/26/20247:02PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/22/20247:00AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
02/22/20246:34AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCULOcular Therapeutix Inc
02/19/20248:00AMPR Newswire (US)AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic ConjunctivitiNASDAQ:OCULOcular Therapeutix Inc
02/15/20247:00AMGlobeNewswire Inc.Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial OfficerNASDAQ:OCULOcular Therapeutix Inc
02/14/20246:48PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCULOcular Therapeutix Inc
02/13/20246:37AMGlobeNewswire Inc.Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMDNASDAQ:OCULOcular Therapeutix Inc
02/06/20245:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/06/20245:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/06/20245:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/06/20245:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/06/20245:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/05/20243:41PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OCULOcular Therapeutix Inc
02/05/20243:39PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OCULOcular Therapeutix Inc
 Showing the most relevant articles for your search:NASDAQ:OCUL

Your Recent History

NASDAQ
EUPXX
Eureka Prime Money Market
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved